Page last updated: 2024-12-11

piroxicam cinnamate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

piroxicam cinnamate: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6436090
CHEMBL ID2106889
CHEBI ID135749
SCHEMBL ID43470
MeSH IDM0160368

Synonyms (29)

Synonym
cinnoxicam
sinartrol
piroxicam cinnamate
spa-s-510
87234-24-0
piroxicam cinnamate (usan)
D05512
CHEBI:135749
A842045
[2-methyl-1,1-bis(oxidanylidene)-3-(pyridin-2-ylcarbamoyl)-1$l^{6},2-benzothiazin-4-yl] (e)-3-phenylprop-2-enoate
(e)-3-phenyl-2-propenoic acid [2-methyl-1,1-dioxo-3-[oxo-(2-pyridinylamino)methyl]-1$l^{6},2-benzothiazin-4-yl] ester
spa-s-51o
CHEMBL2106889
piroxicam cinnamate [usan]
piroxicam cinnamic acid ester
2-propenoic acid, 3-phenyl-, 2-methyl-3-((2-pyridinylamino)carbonyl)-2h-1,2-benzothiazin-4-yl ester, s,s-dioxide
unii-7e8q32n75n
7e8q32n75n ,
4-hydroxy-2-methyl-n-2-pyridyl-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide, cinnamate (ester)
AKOS015896439
piroxicam cinnamate [who-dd]
piroxicam cinnamic acid ester [mi]
SCHEMBL43470
DTXSID10236212
[2-methyl-1,1-dioxo-3-(pyridin-2-ylcarbamoyl)-1lambda6,2-benzothiazin-4-yl] (e)-3-phenylprop-2-enoate
spa-s 510; sinartol; sinartrol; zelis; zen
Q27268143
CS-0026104
HY-106583
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cinnamate ester
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1678479Inhibition of recombinant His6-tagged SARS-CoV-2 main protease using Dabcyl-KTSAVLQ-SGFRKM-E(Edans-NH2) as substrate preincubated for 15 mins followed by substrate addition by FRET based assay2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
AID1678478Inhibition of recombinant His6-tagged SARS-CoV-2 main protease assessed as residual enzyme activity at 100 uM using Dabcyl-KTSAVLQ-SGFRKM-E(Edans-NH2) as substrate preincubated for 15 mins followed by substrate addition by FRET based assay relative to con2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (18.18)18.7374
1990's5 (45.45)18.2507
2000's2 (18.18)29.6817
2010's1 (9.09)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.89 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (28.57%)5.53%
Reviews1 (7.14%)6.00%
Case Studies1 (7.14%)4.05%
Observational0 (0.00%)0.25%
Other8 (57.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]